Henggui Hu
Henggui Hu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Kefeng Zhai
School of Biological and Food Engineering, Engineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, Suzhou University, Suzhou, Anhui, 234000, China
5 shared publications - Ghulam Jilany Khan
Department of Pharmacology and Therapeutics, Faculty of Pharmacy, University of Central Punjab, Lahore 54000, Pakistan
3 shared publications Chenghui He
College of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China
2 shared publicationsHong Duan
Engineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, School of Biological and Food Engineering, Suzhou University, Suzhou, Anhui, 234000, China; College of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China
2 shared publications- Hong Duan
School of Biological and Food Engineering, Anhui Polytechnic University, Wuhu, People’s Republic of China
2 shared publications Jianhua Yang
Department of Pharmacy Xinjiang Key Laboratory of Clinical Drug Research The First Affiliated Hospital of Xinjiang Medical University 830011 Urumqi China
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 15 (5)
Schisandrin A ameliorates endoplasmic reticulum stress mediated apoptosis in metabolic associated fatty liver disease
Background: Metabolic associated fatty liver disease (MAFLD) is closeky linked to metabolic disorders and lack of effective therapeutic options. Schisandrin A (SA), derived from the traditional Chinese medicinal herb Schisandra, has shown liver-protective properties. SA may counteract MAFLD by modulating endoplasmic reticulum stress (ERS) and inhibiting apoptosis. This study aimed to investigate the protective effects of SA on high-fat diet-induced MAFLD in C57BL/6 mice. The study also sought to elucidate the underlying mechanisms, focusing on the ERS signaling pathway and apoptosis. Methods: MAFLD mice models were induced with a high-fat diet and divided into control, model, SA intervention (various dosages), atorvastatin positive control, and ERS inhibitor combined with SA intervention groups. serum lipid profiles, liver enzymes, and liver histopathology were assessed. Western blot, immunofluorescence, and TUNEL assay were used to evaluate ERS and apoptosis-related protein expression. Results: SA intervention markedly enhanced serum lipid profiles and reduced liver enzyme levels. The histopathological alterations observed in the model group were significantly mitigated by SA treatment. Western blot analysis revealed that SA effectively modulated the expression levels of proteins associated with ERS and apoptosis. Furthermore, immunofluorescence and TUNEL assay results substantiated SA's regulatory influence on ERS and apoptotic pathways. Conclusion: SA effectively improved dyslipidemia and hepatic lipid metabolism abnormalities. It reduced hepatic lipid deposition and pathological damage in MAFLD mice induced by a high-fat diet. The mechanism of action may involve the regulation of the ERS signaling pathway, thereby protecting cells from apoptosis.
- 1 May 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 15 (5)
Open AccessSchisandrin A ameliorates endoplasmic reticulum stress mediated apoptosis in metabolic associated fatty liver disease
Background: Metabolic associated fatty liver disease (MAFLD) is closeky linked to metabolic disorders and lack of effective therapeutic options. Schisandrin A (SA), derived from the traditional Chinese medicinal herb Schisandra, has shown liver-protective properties. SA may counteract MAFLD by modulating endoplasmic reticulum stress (ERS) and inhibiting apoptosis. This study aimed to investigate the protective effects of SA on high-fat diet-induced MAFLD in C57BL/6 mice. The study also sought to elucidate the underlying mechanisms, focusing on the ERS signaling pathway and apoptosis. Methods: MAFLD mice models were induced with a high-fat diet and divided into control, model, SA intervention (various dosages), atorvastatin positive control, and ERS inhibitor combined with SA intervention groups. serum lipid profiles, liver enzymes, and liver histopathology were assessed. Western blot, immunofluorescence, and TUNEL assay were used to evaluate ERS and apoptosis-related protein expression. Results: SA intervention markedly enhanced serum lipid profiles and reduced liver enzyme levels. The histopathological alterations observed in the model group were significantly mitigated by SA treatment. Western blot analysis revealed that SA effectively modulated the expression levels of proteins associated with ERS and apoptosis. Furthermore, immunofluorescence and TUNEL assay results substantiated SA's regulatory influence on ERS and apoptotic pathways. Conclusion: SA effectively improved dyslipidemia and hepatic lipid metabolism abnormalities. It reduced hepatic lipid deposition and pathological damage in MAFLD mice induced by a high-fat diet. The mechanism of action may involve the regulation of the ERS signaling pathway, thereby protecting cells from apoptosis.
- 9 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 121028
Dual targeting by Artemisia rupestris L. disrupting TLR4/NF-κB signaling and macrophage driven immune evasion in hepatocellular carcinoma
- 9 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 121028
Dual targeting by Artemisia rupestris L. disrupting TLR4/NF-κB signaling and macrophage driven immune evasion in hepatocellular carcinoma
- Open Access
- 23 June 2025
- Published by Elsevier in Translational Oncology
- Vol. 59, 102447
miR-23b is a negative regulator of tumor suppressing PTPRG in colorectal cancer
- 23 June 2025
- Published by Elsevier in Translational Oncology
- Vol. 59, 102447
Open AccessmiR-23b is a negative regulator of tumor suppressing PTPRG in colorectal cancer
- Top Cited Papers
- 7 January 2025
- Published by Elsevier in Phytomedicine
- Vol. 138, 156370
Anti-colorectal cancer actions of Glycyrrhiza uralensis Fisch. and its underlying mechanism via HPLC integration and network pharmacological approaches
- 7 January 2025
- Published by Elsevier in Phytomedicine
- Vol. 138, 156370
Top Cited PapersAnti-colorectal cancer actions of Glycyrrhiza uralensis Fisch. and its underlying mechanism via HPLC integration and network pharmacological approaches
- Open Access
- 1 November 2024
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 13 (6) , 3245-3255
The potential mechanism of Isodon suzhouensis against COVID-19 via EGFR/TLR4 pathways
Corona Virus Disease 2019 (COVID-19) has brought the new challenges to scientific research. Isodon suzhouensis has good anti-inflammatory and antioxidant stress effects, which is considered as a potential treatment for COVID-19. The possibility for the treatment of COVID-19 with suzhouensis and its potential mechanism of action were explored by employing molecular docking and network pharmacology. Network pharmacology and molecular docking were used to screen drug targets, and Lipopolysaccharide (LPS) induced RAW264.7 and NR8383 cells inflammation model was used for experimental verification. Collectively a total of 209 possible linkages against 18 chemical components from suzhouensis and 1194 COVID-19 related targets were selected. Among these, 164 common targets were obtained from the intersection of suzhouensis and COVID-19. GO and KEGG enriched 582 function targets and 87 target proteins pathways, respectively. The results from molecular docking studies revealed that rutin, vitexin, isoquercitrin and quercetin had significant binding ability with SARS-CoV-23CLpro and ACE2. In vitro studies showed that Isodon suzhouensis extract (ISE) may inhibit the activation of PI3K/Akt pathway and the expression level of downstream pro-inflammatory factors by inhibiting the activation of EGFR in RAW264.7 cells induced by LPS. In addition, ISE was able to inhibit the activation of TLR4/NF-κB signaling pathway in NR8383 cells exposed to LPS. Overall, the network pharmacology and in vitro studies conclude that active components from suzhouensis have strong therapeutic potential against COVID-19 through multi-target, multi-pathway dimensions and can be a promising candidate against COVID-19.
- 1 November 2024
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 13 (6) , 3245-3255
Open AccessThe potential mechanism of Isodon suzhouensis against COVID-19 via EGFR/TLR4 pathways
Corona Virus Disease 2019 (COVID-19) has brought the new challenges to scientific research. Isodon suzhouensis has good anti-inflammatory and antioxidant stress effects, which is considered as a potential treatment for COVID-19. The possibility for the treatment of COVID-19 with suzhouensis and its potential mechanism of action were explored by employing molecular docking and network pharmacology. Network pharmacology and molecular docking were used to screen drug targets, and Lipopolysaccharide (LPS) induced RAW264.7 and NR8383 cells inflammation model was used for experimental verification. Collectively a total of 209 possible linkages against 18 chemical components from suzhouensis and 1194 COVID-19 related targets were selected. Among these, 164 common targets were obtained from the intersection of suzhouensis and COVID-19. GO and KEGG enriched 582 function targets and 87 target proteins pathways, respectively. The results from molecular docking studies revealed that rutin, vitexin, isoquercitrin and quercetin had significant binding ability with SARS-CoV-23CLpro and ACE2. In vitro studies showed that Isodon suzhouensis extract (ISE) may inhibit the activation of PI3K/Akt pathway and the expression level of downstream pro-inflammatory factors by inhibiting the activation of EGFR in RAW264.7 cells induced by LPS. In addition, ISE was able to inhibit the activation of TLR4/NF-κB signaling pathway in NR8383 cells exposed to LPS. Overall, the network pharmacology and in vitro studies conclude that active components from suzhouensis have strong therapeutic potential against COVID-19 through multi-target, multi-pathway dimensions and can be a promising candidate against COVID-19.